IQWiG News

Latest Articles

• IQWiG Assessment Finds No Added Benefit for Guselkumab Over Golimumab in Ulcerative Colitis Patients

  Published: Mar 28, 2026

  Section: Research

  The German Institute for Quality and Efficiency in Health Care (IQWiG) has concluded its benefit assessment for the monoclonal antibody guselkumab in treating ulcerative colitis. D...

• German Health Institute Reports Minor Added Benefit for Guselkumab in Specific Chronic Crohn’s Disease Subgroups

  Published: Mar 28, 2026

  Section: Science & Tech

  The Institute for Quality and Efficiency in Health Care (IQWiG) has released a benefit assessment for guselkumab, evaluating its efficacy in treating ulcerative colitis and Crohn’s...